[go: up one dir, main page]

KR950010907A - 생리 활성 펩티드 조성물 - Google Patents

생리 활성 펩티드 조성물 Download PDF

Info

Publication number
KR950010907A
KR950010907A KR1019940026767A KR19940026767A KR950010907A KR 950010907 A KR950010907 A KR 950010907A KR 1019940026767 A KR1019940026767 A KR 1019940026767A KR 19940026767 A KR19940026767 A KR 19940026767A KR 950010907 A KR950010907 A KR 950010907A
Authority
KR
South Korea
Prior art keywords
hydroxyapatite
bioactive
bioactive peptide
physiologically active
composition according
Prior art date
Application number
KR1019940026767A
Other languages
English (en)
Inventor
아끼라 야나가와
Original Assignee
야나가와 히로미
유겡가이샤 돗트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 야나가와 히로미, 유겡가이샤 돗트 filed Critical 야나가와 히로미
Publication of KR950010907A publication Critical patent/KR950010907A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

생리 활성 펩티드가 특정 캐리어 내에 균일하게 분산되고 그 캐리어위에 균일하게 흡착되어 있는 생리 활성 펩티드 조성물. 이 생리 활성 펩티드 조성물은 히드록시아파티트내에 균일하게 분산되고 그 위에 균일하게 흡착된 생리적 유효량의 생리 활성 펩티드틀 함유한다.
조성물은 분말 형태로 비내 투여가능하다.

Description

생리 활성 펩티드 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (13)

  1. 생리 활성 펩티드 및 히드록시아파티트를 함유하고, 상기 생리 활성 펩티드의 생리적 유효량이 상기 히드록시아파티트내에 균일하게 분산되고 히드록시아파티트상에 균일하게 흡착되어 있으며, 상기 히드록시아파티트의 평균 입자 크기가 20㎛ 내지 250㎛의 범위임을 특징으로 하는 생리 활성 펩티드 조성물.
  2. 제1항에 있어서, 히드록시아파티트의 평균 입자 크기가 30㎛ 내지 60㎛의 범위임을 특징으로 하는 생리 활성 펩티드 조성물.
  3. 제1항 또는 2항에 있어서, 아스파르트산이 안정화제로서 추가로 함유됨을 특징으로 하는 생리 활성 펩티드 조성물.
  4. 제1항에 있어서, 상기 생리 활성 펩티드가 펩티드 호르몬, 생리 활성 단백질 또는 효소 단백질임을 특징으로 하는 생리 활성 펩티드 조성물.
  5. 제1항에 있어서, 상기 생리 활성 펩티드가 칼시토닌이고, 상기 칼시토닌이 평균 입자 크기가 20㎛ 내지 250㎛인 히드록시아파티트내에 균일하게 분산되고 그 위에 균일하게 흡착되어 있는 생리 활성 펩티드 조성물.
  6. 제1항에 있어서, 상기 생리 활성 펩티드가 인슐린이고, 상기 인슐린이 평균 입자 크기가 20㎛ 내지 250㎛인 히드록시아파티트내에 균일하게 분산되고 그 위에 균일하게 흡착되어 있는 생리 활성 펩티드 조성물.
  7. 제1항 내지 6항중 어느 한 항에 있어서, 상기 조성물이 분말 형태로 비내 투여가능함을 특징으로 하는 생리 활성 펩티드 조성물.
  8. 제3항에 있어서, 상기 조성물이 분말 형태로 비내 투여가능함을 특징으로 하는 생리 활성 펩티드 조성물.
  9. 제6항에 있어서, 상기 조성물이 분말 형태로 비내 투여가능함을 특징으로 하는 생리 활성 펩티드 조성물.
  10. 제7항에 있어서, 상기 조성물이 분말 형태로 비내 투여가능함을 특징으로 하는 생리 활성 펩티드 조성물.
  11. 캐리어가 평균 입자 크기가20㎛내지 250㎛인 히드록시아파티트의 미세 분할 입자임을 특징으로 하는, 생리 활성 물질을 함유한 비내 투여용 조성물에 사용되는 캐리어.
  12. 제11항에 있어서. 히드록시아파티트의 평균 입자 크기가 30㎛ 내지 60㎛의 범위임을 특징으로 캐리어.
  13. 제11항 또는 12항에 있어서, 생리 활성 물질이 생리 활성 펩티드임을 특징으로 캐리어.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019940026767A 1993-10-19 1994-10-19 생리 활성 펩티드 조성물 KR950010907A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP93-284423 1993-10-19
JP28442393 1993-10-19
JP6155456A JPH07165613A (ja) 1993-10-19 1994-06-15 経鼻吸収薬物用キャリヤおよび生理活性ペプチド組成物
JP94-155456 1994-06-15

Publications (1)

Publication Number Publication Date
KR950010907A true KR950010907A (ko) 1995-05-15

Family

ID=26483458

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940026767A KR950010907A (ko) 1993-10-19 1994-10-19 생리 활성 펩티드 조성물

Country Status (5)

Country Link
US (1) US5574006A (ko)
EP (1) EP0648498A1 (ko)
JP (1) JPH07165613A (ko)
KR (1) KR950010907A (ko)
CN (1) CN1120458A (ko)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3414539B2 (ja) * 1994-05-11 2003-06-09 有限会社ドット 経鼻吸収用組成物
US6096324A (en) * 1995-06-13 2000-08-01 Laboratory Skin Care Methods of delivering materials into the skin, and compositions used therein
DE19733651A1 (de) * 1997-08-04 1999-02-18 Boehringer Ingelheim Pharma Wässrige Aerosolzubereitungen enthaltend biologisch aktive Markomoleküle und Verfahren zur Erzeugung entsprechender Aerosole
US20060239930A1 (en) * 1997-08-04 2006-10-26 Herbert Lamche Process for nebulizing aqueous compositions containing highly concentrated insulin
US20070009605A1 (en) * 1998-07-23 2007-01-11 Ignatious Francis X Encapsulation of water soluble peptides
SE9803770D0 (sv) * 1998-11-05 1998-11-05 Astra Ab Dry powder pharmaceutical formulation
JP2002348234A (ja) * 2001-05-28 2002-12-04 Purotekku:Kk 薬物封入無機物微粒子、その製造法及び薬物封入無機物微粒子製剤
BR0214438A (pt) * 2001-11-26 2004-11-03 Daiichi Suntory Pharma Co Ltd Composição farmacêutica para absorção nasal
WO2004073729A1 (ja) 2003-02-21 2004-09-02 Translational Research Ltd. 薬物の経鼻投与用組成物
US20040180091A1 (en) * 2003-03-13 2004-09-16 Chang-Yi Lin Carbonated hydroxyapatite-based microspherical composites for biomedical uses
US7812120B2 (en) * 2003-03-21 2010-10-12 Par Pharmaceutical, Inc. Nasal calcitonin formulations containing chlorobutanol
KR100974482B1 (ko) 2003-03-27 2010-08-10 가부시키가이샤 바이오악티스 비강용 분말 약제 투약 장치
US8673360B2 (en) 2004-08-10 2014-03-18 Shin Nippon Biomedical Laboratories, Ltd. Compositions that enable rapid-acting and highly absorptive intranasal administration
KR20070060950A (ko) * 2004-10-07 2007-06-13 가부시키가이샤 상기 경피·경점막 흡수 제제
WO2006109635A1 (ja) 2005-04-06 2006-10-19 Kabushiki Kaisha Sangi 腸管吸収用抗腫瘍剤
CN101229378A (zh) * 2005-05-05 2008-07-30 国家淀粉及化学投资控股公司 用于送递活性剂的组合物
CN101668544B (zh) * 2006-12-26 2013-04-24 株式会社新日本科学 经鼻投用制剂
EP2077132A1 (en) 2008-01-02 2009-07-08 Boehringer Ingelheim Pharma GmbH & Co. KG Dispensing device, storage device and method for dispensing a formulation
WO2010112358A2 (de) 2009-03-31 2010-10-07 Boehringer Ingelheim International Gmbh Verfahren zur beschichtung einer oberfläche eines bauteils
US9101539B2 (en) 2009-05-15 2015-08-11 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
WO2010133294A2 (de) 2009-05-18 2010-11-25 Boehringer Ingelheim International Gmbh Adapter, inhalationseinrichtung und zerstäuber
US8827946B2 (en) 2009-07-31 2014-09-09 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
JP5715640B2 (ja) 2009-11-25 2015-05-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ネブライザ
JP5658268B2 (ja) 2009-11-25 2015-01-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ネブライザ
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
CN101721687B (zh) * 2010-01-21 2012-08-15 中国药科大学 胰岛素-羟基磷灰石纳米复合物及其制备方法和应用
JP5874724B2 (ja) 2010-06-24 2016-03-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ネブライザ
EP2694220B1 (de) 2011-04-01 2020-05-06 Boehringer Ingelheim International GmbH Medizinisches gerät mit behälter
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
WO2013152894A1 (de) 2012-04-13 2013-10-17 Boehringer Ingelheim International Gmbh Zerstäuber mit kodiermitteln
EP3030298B1 (en) 2013-08-09 2017-10-11 Boehringer Ingelheim International GmbH Nebulizer
ES2836977T3 (es) 2013-08-09 2021-06-28 Boehringer Ingelheim Int Nebulizador
IL247927B (en) 2014-05-07 2022-09-01 Boehringer Ingelheim Int Container, nebulizer and use
NZ724724A (en) 2014-05-07 2022-01-28 Boehringer Ingelheim Int Container, indicator device, and nebulizer
EP3139984B1 (en) 2014-05-07 2021-04-28 Boehringer Ingelheim International GmbH Nebulizer
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4371523A (en) * 1980-12-29 1983-02-01 The Regents Of The University Of California Reducing the aggregation of insulin in solution
US5009898A (en) * 1988-09-29 1991-04-23 Kabushiki Kaisha Sangi Antimicrobial hydroxyapatite powders and methods for preparing them
US5055307A (en) * 1988-12-29 1991-10-08 Asahi Kagaku Kogyo Kabushiki Kaisha Slow release drug delivery granules and process for production thereof
JPH02180707A (ja) * 1988-12-31 1990-07-13 Tonen Corp リン酸化合物粒子集合体の製造方法
US5116729A (en) * 1989-03-10 1992-05-26 Miles Inc. Stabilization of oxidase enzyme-based test strips
DE4140689B4 (de) * 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalationspulver und Verfahren zu ihrer Herstellung
JPH05255095A (ja) * 1992-03-13 1993-10-05 Advance Co Ltd 血管内投与剤
KR940006601A (ko) 1992-09-12 1994-04-25 야나가와 히로미 생리활성 펩티드 조성물

Also Published As

Publication number Publication date
EP0648498A1 (en) 1995-04-19
CN1120458A (zh) 1996-04-17
US5574006A (en) 1996-11-12
JPH07165613A (ja) 1995-06-27

Similar Documents

Publication Publication Date Title
KR950010907A (ko) 생리 활성 펩티드 조성물
ATE159284T1 (de) Feuchttigkeitsbeständige zusammensetzung
MX171352B (es) Particulas de perfume revestidas
ES2148163T3 (es) Microcapsula agricola y produccion de la misma.
MX172840B (es) Composiciones de atomizador para cabello a base de silicon
PE79099A1 (es) Formulaciones de insulina estables
CA2041093A1 (en) A pharmacological composition containing polyelectrolyte complexes in microparticulate form and at least one active substance
EE04223B1 (et) Interferooni stabiilne vedelkompositsioon, mis sisaldab aminohappeid
ES2074083T3 (es) Composiciones coloreadas para recubrimientos en polvo.
SG50480A1 (en) Gastrointestinal mucosa-adherent matrixes pharmaceutical preparations and a coating composition
EP0428038A3 (en) Transdermal application of 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol
ES2164691T3 (es) Formulacion de insulina.
CA2220871A1 (en) Peptide/protein suspending formulations
CA2292730A1 (en) Stabilized antibody formulation
TNSN98087A1 (fr) Composition pharmaceutique en aerosol
ES2086377T3 (es) Procedimiento para tratar o revestir un sustrato con una composicion acuosa y uso de dichas composiciones.
DE3278263D1 (en) Composition for coating food and drugs, and granules so coated
MX2007005931A (es) Composicion granulada.
KR850700218A (ko) 약학 조성물
KR940006601A (ko) 생리활성 펩티드 조성물
SE9700134D0 (sv) New formulation
CA2339836A1 (en) Active ingredient support in the form of a film
ATE227562T1 (de) Vorrichtung zur verteilung einer therapeutischen oder kosmetischen substanz, wobei der inerte träger hexamethyldisiloxan ist und zusammensetzung für den gebrauch in dieser vorrichtung
KR920012357A (ko) 접착제 조성물 및 금속 접합체
MY106039A (en) Anti-dazzling and electrostatic charge-preventive transparent coating material,method thereof and video display coated therewith.

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19941019

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19990701

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19941019

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20010629

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20010927

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20010629

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I